The humanized IgG1 monoclonal antibody bimekizumab is designed to selectively target and suppress the pro-inflammatory cytokines IL-17A and IL-17F, both associated with autoimmune disorders (81). The gene discussed is IL17A; the disease is autoimmune disease.